CCA
STRO icon

Catalyst Capital Advisors’s Sutro Biopharma STRO Stock Holding History

Catalyst Capital Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-50
Closed -$6K – 472
2019
Q1 		$6K Hold
50
– – ﹤0.01% 350
2018
Q4 		$5K Hold
50
– – ﹤0.01% 365
2018
Q3 		$8K Buy
+50
New +$7.55K ﹤0.01% 353

Other funds holding STRO

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Catalyst Capital Advisors's STRO Position: Q2 2019 in Review

Catalyst Capital Advisors sold out of Sutro Biopharma (STRO) in Q2 2019, closing a stake of 50 shares — an estimated $6K sold.

Catalyst Capital Advisors first reported a position in STRO in Q3 2018 and held it in 3 quarters. The position peaked at $8K in Q3 2018. 58 funds tracked by Wall St. Rank hold STRO as of Q2 2019.

  • Catalyst Capital Advisors reported no remaining Sutro Biopharma position as of Q2 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 50 Sutro Biopharma shares in Q2 2019, an estimated $6K.
  • Catalyst Capital Advisors first reported a position in Sutro Biopharma in Q3 2018 and held it in 3 quarters.
  • Catalyst Capital Advisors's Sutro Biopharma position peaked at $8K in Q3 2018.
  • 58 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2019.

Based on Catalyst Capital Advisors's 13F filing for Q2 2019, filed 8 Aug 2019.